Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma.
Besides, mammalian target of rapamycin inhibition has the ability to modulate T-lymphocyte homeostasis. Here, we report the case of a metastatic renal cell carcinoma patient treated with everolimus who presented unexpected prolonged tumor response. The monitoring of immune responses showed strong antitumor T-cell activation at the time of disease control, whereas a profound immunosuppression occurred when tumor progressed. Thus, a change of immune functions is associated with everolimus treatment. Our observation suggests that everolimus could shape immune responses, which in turn could contribute to its efficacy.
Written by:
Thiery-Vuillemin A, Laheurte C, Mansi L, Royer B, Pivot X, Borg C, Adotevi O. Are you the author?
Oncologie, Besançon Cedex; CIC-BT506, CHRU; INSERM, UMR1098, UMR1098; Université de Franche-Comté; EFS Bourgogne Franche-Comté; Laboratoire de Pharmacologie Clinique et Toxicologie, Besançon, France.
Reference: J Immunother. 2014 Jan;37(1):51-4.
doi: 10.1097/CJI.0000000000000006
PubMed Abstract
PMID: 24316556
UroToday.com Renal Cancer Section
